Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Some drugs linked to growth hormones may increase the chance of hair loss in women.

A new small peptide may help hair growth by activating a specific receptor and should be tested in humans.

GLP-1 therapies can cause hair loss, but hair often regrows after stopping or reducing the drug.

Ginsenoside compound K shows promise for treating metabolic diseases like diabetes and obesity.

Semaglutide is an effective weekly treatment for obesity, promoting weight loss and improving health, despite some side effects.

Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.

Formyl-peptide receptor agonists could be new anti-inflammatory drugs.

Certain peptides can prevent hair loss in young rats caused by a cancer drug.

The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.

A peptide known for reducing wrinkles also effectively inhibits an enzyme linked to skin inflammation and acne.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

dAR-6–1 is a promising new treatment for hair loss that works better than minoxidil.

The compound GD-23 may reduce anxiety like diazepam by targeting the TSPO receptor.

Targeting glucocorticoid action might help treat type-2 diabetes, but human trials are needed.

Pioglitazone may help treat lichen planopilaris, but more research is needed.

Changing the 6-position on benzopyran molecules affects insulin release, with some compounds showing strong inhibitory effects.

New research on prostamide F2α has led to treatments for glaucoma and eyelash growth and may have more medical uses.

The new anti-acne treatment HA-P5 effectively reduces acne by targeting two key receptors and avoids an enzyme that can hinder treatment.

TAT-GILZ peptide promotes hair growth by boosting stem cell activity.

Metformin and liraglutide improved symptoms of HAIR-AN syndrome in a child.

Allopregnanolone is needed for certain brain processing issues caused by D1 dopamine receptor activation.

PPAR agonists show promise for skin conditions but need more research before being a main treatment.

PPAR-γ helps control skin oil glands and inflammation, and its disruption can cause hair loss diseases.

Improved CRBN ligands make protein degraders more effective and drug-like.

RADA16-I can effectively deliver and release mangiferin, improving its solubility and bioavailability.

Troglitazone increases subcutaneous fat in lipodystrophy patients.

Pioglitazone, Trimipramine, and Dimetindene may be repurposed to treat psoriasis.

Glibenclamide slows breast cancer cell growth by stopping cell division.